DAVID RYAN: Open Payments
NPI 1912918129 · KENNEWICK, WA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,844 in 95 payments from 15 companies in 2025. Trend: 2023 $2,272 · 2024 $2,078 · 2025 $1,844
Food & beverage: $1,844
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 19 | $374 |
| AstraZeneca Pharmaceuticals LP | 10 | $335 |
| GlaxoSmithKline, LLC. | 15 | $247 |
| PFIZER INC. | 15 | $224 |
| Otsuka America Pharmaceutical, Inc. | 17 | $216 |
| Vanda Pharmaceuticals Inc. | 3 | $100 |
| Lilly USA, LLC | 5 | $94 |
| ABBVIE INC. | 2 | $53 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 2 | $44 |
| Novo Nordisk Inc | 2 | $34 |
Products named: CAPLYTA, REXULTI, FARXIGA, TRELEGY ELLIPTA, ELIQUIS, SHINGRIX, NURTEC ODT, LOKELMA.
Industry payments across WA — which companies pay providers there.
